Skip to main content
Anand Karnad, MD, Oncology, San Antonio, TX

AnandBKarnadMD

Oncology San Antonio, TX

Hematologic Oncology

Physician

Dr. Karnad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Karnad's full profile

Already have an account?

  • Office

    7979 Wurzbach Rd
    San Antonio, TX 78229
    Phone+1 210-450-1000
    Fax+1 210-450-1150

Education & Training

  • Boston University Medical Center
    Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1989
  • East Tennessee State University/Quillen College of Medicine
    East Tennessee State University/Quillen College of MedicineResidency, Internal Medicine, 1982 - 1984
  • Madras Medical College
    Madras Medical CollegeClass of 1981

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2004 - 2025
  • TN State Medical License
    TN State Medical License 1984 - 2004
  • GA State Medical License
    GA State Medical License 1983 - 1989
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
    Anand Karnad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

  • Mesa Departing March 2023
    Mesa Departing March 2023December 12th, 2022
  • FDA Approves Immunotherapy Drug as First-Line Cancer Treatment
    FDA Approves Immunotherapy Drug as First-Line Cancer TreatmentNovember 11th, 2016
  • Battling Cancer with Immunotherapy
    Battling Cancer with ImmunotherapyNovember 11th, 2016

Grant Support

  • Protocol Review And Monitoring SystemNational Cancer Institute2009–2011
  • Clinical Trial: A PH II Study Of CNTO 328 Antibody Against IL-6 In PTS With PROSNational Center For Research Resources2008

Professional Memberships

Other Languages

  • Hindi, Tamil, Urdu